Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Irritable Bowel Syndrome III: Medical and Nursing Management

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Esophageal Self-Dilation in Benign Refractory Esophageal Strictures: Outcomes from a Randomized Controlled Trial and a Prospective Observational Study.

Digestive diseases and sciences·2024

Same author

Coeliac disease is a strong risk factor for Gastro-oesophageal reflux disease while a gluten free diet is protective: a systematic review and meta-analysis.

EClinicalMedicine·2024

Same author

Self-Dilation of Refractory Benign Esophageal Strictures.

The American journal of gastroenterology·2021

Same author

A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy.

Clinical journal of gastroenterology·2021

Same author

Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population-based study.

Alimentary pharmacology & therapeutics·2021

Same author

Pseudodiverticulum at the myotomy site in achalasia: Significant finding or overblown?

Gastrointestinal endoscopy·2021

Search research articles

Related Experiment Video

Updated: May 16, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

New treatments for IBS.

Magnus Halland¹, Nicholas J Talley

¹University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.

Nature Reviews. Gastroenterology & Hepatology

|November 14, 2012

Summary

Irritable Bowel Syndrome (IBS) treatments are improving, with new options offering better symptom relief. Personalized management and avoiding harm are key to effective IBS therapy.

Area of Science:

Gastroenterology
Clinical Therapeutics
Patient Outcomes

Background:

Irritable Bowel Syndrome (IBS) affects 5-20% of Western populations.
Key symptoms include abdominal pain, altered bowel habits, and bloating.
Current treatments offer inadequate relief for many patients, highlighting an unmet need.

Purpose of the Study:

To review the latest pharmacological and nonpharmacological treatments for IBS.
To discuss emerging and future therapeutic approaches for IBS.
To provide data on number needed to treat and number needed to harm for selected IBS therapies.

Main Methods:

Literature review of recent IBS treatment research.
Inclusion of novel nonpharmacological and pharmacological interventions.

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

Related Experiment Videos

Last Updated: May 16, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

Analysis of data supporting efficacy and safety of IBS treatments.

Main Results:

Novel treatments show promise for improved IBS symptom management.
Internet-based behavioral therapy delivery is being explored.
Estimates for number needed to treat and number needed to harm are provided for select IBS therapies.

Conclusions:

The future of IBS therapeutics is optimistic with ongoing research.
Individualized management is crucial for optimizing IBS therapy outcomes.
Balancing efficacy with harm avoidance is essential for patient care.